PR
PureTech Health plc
PRTC · NASDAQ
$17.42 -0.06% (-$0.01)
Market Cap $424.1M
P/E Ratio -
Div. Yield -
ROE 30.94%
Bulios Fair Price
$21.71
24.6% upside
Current Price
$17.42
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PRTC is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
50 /100
Fair P/B 1.36x
P/S 91.02x
EV/EBITDA N/A
Growth
78 /100
Growing Book val. growth 16.82%
Rev. growth 30.63%
FCF growth N/A
Profitability
20 /100
Weak Net margin 2,355.42%
Op. margin 2,114.72%
FCF margin 1,831.64%
Quality
0 /100
Poor ROE 30.94%
ROA 20.52%
Asset turnover 0.01x
Debt
69 /100
Low Current ratio 6.59x
Int. coverage -1.42x
Debt/Equity 0.06x
Stability
33 /100
Unstable Rev. volatility 32.92%
EPS volatility 1,433.04%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRTC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert William Henry Lyne
Employees
56
Headquarters
Boston